Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

3O8:GR

19.090 EUR 0.227 1.20%

As of 02:08:46 ET on 05/25/2015.

Snapshot for Omeros Corp (3O8)

Open: 19.090 Day's Range: 19.090 - 19.090 Volume: 0
Previous Close: 18.863 52wk Range: 8.087 - 24.515 1-Yr Rtn: +133.49%

Stock Chart for 3O8

No chart data available.
  • 3O8:GR 19.090
  • 1M
  • 1Y
18.863
Interactive 3O8 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 3O8

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -1.6820
Est. PEG Ratio -
Market Cap (M EUR) 722.22
Shares Outstanding (M) 37.83
30 Day Average Volume 130
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 3O8

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for 3O8

Omeros Corporation is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management.

Gregory A DemopulosChairman/Pres/CEO/Co-FounderMichael A JacobsenVP:Finance/Chief Acctg Officer
George A GaitanarisVP:Science/Chief Scientific OfcrJ Steven WhitakerVP:Clinical/Chief Medical Ofcr
More Company Profile & Key Executives for 3O8

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil